Seroepidemiology of mumps in Europe (1996–2008): why do outbreaks occur in highly vaccinated populations?

Epidemiology and Infection

Epidemiology and Infection / Volume 141 / Issue 03 / March 2013, pp 651-666
Copyright © Cambridge University Press 2012
DOI: http://dx.doi.org/10.1017/S0950268812001136 (About DOI), Published online: 12 June 2012

Table of Contents - March 2013 - Volume 141, Issue 03

Original Papers

Vaccination

Seroepidemiology of mumps in Europe (1996–2008): why do outbreaks occur in highly vaccinated populations?

Article author query
eriksen j [PubMed] [Google Scholar]
davidkin i [PubMed] [Google Scholar]
kafatos g [PubMed] [Google Scholar]
andrews n [PubMed] [Google Scholar]
barbara c [PubMed] [Google Scholar]
cohen d [PubMed] [Google Scholar]
duks a [PubMed] [Google Scholar]
griskevicius a [PubMed] [Google Scholar]
johansen k [PubMed] [Google Scholar]
bartha k [PubMed] [Google Scholar]
kriz b [PubMed] [Google Scholar]
mitis g [PubMed] [Google Scholar]
mossong j [PubMed] [Google Scholar]
nardone a [PubMed] [Google Scholar]
o'flanagan d [PubMed] [Google Scholar]
de ory f [PubMed] [Google Scholar]
pistol a [PubMed] [Google Scholar]
theeten h [PubMed] [Google Scholar]
prosenc k [PubMed] [Google Scholar]
slacikova m [PubMed] [Google Scholar]
pebody r [PubMed] [Google Scholar]

J. ERIKSEN^a1^a2, I. DAVIDKIN^a3, G. KAFATOS^a2, N. ANDREWS^a2, C. BARBARA^a4, D. COHEN^a5, A. DUKS^a6, A. GRISKEVICIUS^a7, K. JOHANSEN^a8, K. BARTHA^a9, B. KRIZ^a10, G. MITIS^a11, J. MOSSONG^a12, A. NARDONE^a2, D. O'FLANAGAN^a13, F. DE ORY^a14, A. PISTOL^a15, H. THEETEN^a16, K. PROSENC^a17, M. SLACIKOVA^a18 and R. PEBODY^a2 ^c1

^a1 European Programme for Intervention Epidemiology Training (EPIET), European Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden

^a2 Health Protection Agency Health Protection Services Colindale, London, UK

^a3 National Institute for Health and Welfare (THL), Helsinki, Finland

^a4 Mater Dei Hospital, Malta

^a5 School of Public Health, Sackler Faculty of Medicine, Tel Aviv University, Israel

^a6 Laboratory of the State Agency Infection Centre, Virology Unit, Riga, Latvia

^a7 National Public Health Surveillance Laboratory, Vilnius, Lithuania

^a8 Swedish Institute for Infectious Disease Control, Stockholm, Sweden

^a9 National Centre for Epidemiology, Budapest, Hungary

^a10 National Institute of Public Health (SZU), Prague, Czech Republic

^a11 Nicosia Hospital, Nicosia, Cyprus

^a12 Surveillance & Epidemiology of Infectious Diseases, Laboratoire National de Santé, Luxembourg

^a13 Health Protection Surveillance Centre, Dublin, Ireland

^a14 Centro Nacional de Microbiología, Instituto de Salud Carlos III, Majadahonda, Madrid, Spain

^a15 National Centre for Communicable Diseases Surveillance and Control, National Institute of Public Health, Romania

^a16 Center for the Evaluation of Vaccination, Vaccine and Infectious Disease Institute (Vaxinfectio), University of Antwerp, Belgium

^a17 Laboratory for Virology, NPHI, Slovenia

^a18 Public Health Authority of the Slovak Republic, Bratislava, Slovak Republic

SUMMARY

Mumps outbreaks have recently been recorded in a number of highly vaccinated populations. We related seroprevalence, epidemiological and vaccination data from 18 European countries participating in The European Sero-Epidemiology Network (ESEN) to their risk of mumps outbreaks in order to inform vaccination strategies. Samples from national population serum banks were collected, tested for mumps IgG antibodies and standardized for international comparisons. A comparative analysis between countries was undertaken using age-specific mumps seroprevalence data and information on reported mumps incidence, vaccine strains, vaccination programmes and vaccine coverage 5–12 years after sera collection. Mean geometric mumps antibody titres were lower in mumps outbreak countries [odds ratio (OR) 0·09, 95% confidence interval (CI) 0·01–0·71)]. MMR1 vaccine coverage ⩾95% remained protective in a multivariable model (P < 0·001), as did an interval of 4–8 years between doses (OR 0·08, 95% CI 0·01–0·85). Preventing outbreaks and controlling mumps probably requires several elements, including high-coverage vaccination programmes with MMR vaccine with 4–8 years between doses.

(Received December 14 2011)

(Revised May 14 2012)

(Accepted May 15 2012)

(Online publication June 12 2012)

Key words

Epidemiology;
mumps;
outbreaks;
serology;
vaccination (immunization)

Correspondence:

^c1 Author for correspondence: Dr R. G. Pebody, HPA Health Protection Services, 61 Colindale Avenue, London NW9 5EQ, UK. (Email: Richard.pebody@hpa.org.uk)

Blog This Article

Blog This Article :

Highlight all

<div style="background: #FFFFFF; margin: 0 10px 10px 0; padding: 0 10px 0 0; text-align: left; font-family: Arial, Helvetica, sans-serif; line-height: 1em;"><div style="font-size: 11px; padding: 0px 0px 10px 0px; font-weight:bold; color: #045989;">Seroepidemiology of mumps in Europe (1996–2008): why do outbreaks occur in highly vaccinated populations?</div><div style="font-size: 11px;"><b>
					J. ERIKSEN,
					I. DAVIDKIN,
					G. KAFATOS,
					N. ANDREWS,
					C. BARBARA,
					D. COHEN,
					A. DUKS,
					A. GRISKEVICIUS,
					K. JOHANSEN,
					K. BARTHA,
					B. KRIZ,
					G. MITIS,
					J. MOSSONG,
					A. NARDONE,
					D. O'FLANAGAN,
					F. DE ORY,
					A. PISTOL,
					H. THEETEN,
					K. PROSENC,
					M. SLACIKOVA
					 and R. PEBODY (2013).	</b><br /><a href="http://journals.cambridge.org/action/displayJournal?jid=HYG">Epidemiology and Infection</a>, <a href="http://journals.cambridge.org/action/displayJournal?jid=HYG&volumeId=141&bVolume=y#loc141>
				 ">Volume 141</a>, <a href="http://journals.cambridge.org/action/displayIssue?jid=HYG&volumeId=141&issueId=03&seriesId=0">Issue03</a>, March 2013 pp 651-666<br/>
<a href="http://journals.cambridge.org/action/displayAbstract?aid=8829670">http://journals.cambridge.org/action/displayAbstract?aid=8829670</a></div></div>